Smoking Cessation and Nicotine Deaddiction - Pipeline Insight, 2024

This “Smoking Cessation and Nicotine Deaddiction - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Smoking Cessation and Nicotine Deaddiction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Smoking Cessation and Nicotine Deaddiction Understanding

Smoking Cessation and Nicotine Deaddiction: Overview

Nicotine is an extremely addictive chemical that is found in the tobacco plant. The addiction to nicotine is both physical and mental habitual users not only crave the chemical but also its effects. Using tobacco can lead to grave complications such as emphysema, lung cancer, stroke, chronic bronchitis, heart disease, and even eye-related conditions. Smoking cessation and nicotine deaddiction becomes imperative for improving the quality of life of people excessively dependent on nicotine.

Smoking Cessation and Nicotine Deaddiction - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Smoking Cessation and Nicotine Deaddiction pipeline landscape is provided which includes the disease overview and Smoking Cessation and Nicotine Deaddiction treatment guidelines. The assessment part of the report embraces, in depth Smoking Cessation and Nicotine Deaddiction commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Smoking Cessation and Nicotine Deaddiction collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Smoking Cessation and Nicotine Deaddiction R&D. The therapies under development are focused on novel approaches to treat/improve Smoking Cessation and Nicotine Deaddiction.

Smoking Cessation and Nicotine Deaddiction Emerging Drugs Chapters

This segment of the Smoking Cessation and Nicotine Deaddiction report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Smoking Cessation and Nicotine Deaddiction Emerging Drugs

Cytisinicline: Achieve Life SciencesThe drug, Cytisinicline by Achieve Life Sciences is in the Phase III stage of drug development process for smoking withdrawal. The drug is now available for licensing. The drug’s dual acting mechanism of action exclusively targets the alpha-4-beta-2 nicotine receptor. It is believed to curb nicotine craving and withdrawal symptoms.

NFL 101: NFL BiosciencesNFL Biosciences’ drug candidate NFL 101 is in the Phase II stage of drug development. According to the observations made in the clinical trial, the drug helped in reducing nicotine dependence in cigarette smokers.

Smoking Cessation and Nicotine Deaddiction: Therapeutic Assessment

This segment of the report provides insights about the different Smoking Cessation and Nicotine Deaddiction drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Smoking Cessation and Nicotine Deaddiction

There are approx. 5+ key companies which are developing the therapies for Smoking Cessation and Nicotine Deaddiction. The companies which have their Smoking Cessation and Nicotine Deaddiction drug candidates in the mid to advanced stage, i.e. phase III include, Achieve Life Sciences and others.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Smoking Cessation and Nicotine Deaddiction pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Smoking Cessation and Nicotine Deaddiction: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Smoking Cessation and Nicotine Deaddiction therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Smoking Cessation and Nicotine Deaddiction drugs.

Smoking Cessation and Nicotine Deaddiction Report Insights

• Smoking Cessation and Nicotine Deaddiction Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Smoking Cessation and Nicotine Deaddiction Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Smoking Cessation and Nicotine Deaddiction drugs?
• How many Smoking Cessation and Nicotine Deaddiction drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Smoking Cessation and Nicotine Deaddiction?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Smoking Cessation and Nicotine Deaddiction therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Smoking Cessation and Nicotine Deaddiction and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Achieve LifeSciences
• NFL Biosciences
• Axsome Therapeutics

Key Products

• Cytisinicline
• NFL 101
• AXS-05

This product will be delivered within 2 business days.